Cancer interception

Cancer Prevention Research

Volumn 4, Issue 6, 2011, Pages 187-192

  Blackburn, Elizabeth H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; C REACTIVE PROTEIN; CELECOXIB; DEXAMETHASONE; FOCAL ADHESION KINASE; K RAS PROTEIN; LENALIDOMIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; OLAPARIB; PROTEIN PATCHED 1; RALOXIFENE; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SMOOTHENED PROTEIN; SOMATOMEDIN; STATIN; TRANSCRIPTION FACTOR GLI1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VISMODEGIB; WART VIRUS VACCINE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; BREAST CANCER; CANCER GROWTH; CANCER INCIDENCE; CANCER INTERCEPTION; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CELL DAMAGE; CELL PROTECTION; CELL STRESS; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL TUMOR; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HYPERTENSION; LOW DRUG DOSE; LUNG CANCER; LUNG TUMOR; METASTASIS; MULTIPLE MYELOMA; NOTE; OROPHARYNX CANCER; PAPILLOMAVIRUS INFECTION; PATIENT EDUCATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRECANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; RNA SEQUENCE; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SMOKING CESSATION; STROKE; TELOMERE; UTERINE CERVIX CANCER; ANIMAL; ARTICLE; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS;

EID: 79957821878     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0195     Document Type: Note

References (52)

1. Keith R, Blatchford PJ, Kittelson J, Minna JD, Kelly K, Massion PP, et al. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res 2011;4:793-802.
2. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011;377:31-41.
3. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A,Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376:1741-50.
4. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010;375:1624-33.
5. Chan A, Sima C, Zauber A, Ridker P, Hawk E, Bertagnolli M. C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev Res 2011 (In press).
6. Meyskens FL Jr, Curt GA, Brenner DE, Gordon G, Herberman RB, Finn O, et al. Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. Cancer Prev Res 2011;4:311-23.
7. Temple R. Cancer chemoprevention-the cardiovascular model. Cancer Prev Res 2011;4:307-10.
8. Gold K, Kim E, Lee JJ, Wistuba I, Farhangfar C, Hong WK. The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res 2011 (In press).
9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
10. Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol 2011;8:184-7.
11. Jordan VC. Antitumour activity of the antioestrogen ICI 46,474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model. J Steroid Biochem 1974;5:354.
12. Vogel VG. Tipping the balance for the primary prevention of breast cancer. J Natl Cancer Inst 2010;102:1683-5.
13. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res 2010;3: 696-706.
14. Bolla M, de Reijke TM, Van Tienhoven G, Van Den Bergh AC, Oddens J, Poortmans PM, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516-27.
15. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-202.
16. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24. (Pubitemid 36859473)
17. Gauthier ML, Berman HK, Miller C, Kozakeiwicz K, Chew K, Moore D, et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell 2007;12:479-91. (Pubitemid 350046408)
18. Michor F, Polyak K. The origins and implications of intratumor heterogeneity. Cancer Prev Res 2010;3:1361-4.
19. Park SY, Gonen M, Kim HJ, Michor F, Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest 2010;120:636-44.
20. Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A 1983;80:3812-5.
21. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51. (Pubitemid 35340782)
22. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006;116:1167-73.
23. Lowy DR, Munger K. Prognostic implications of HPV in oropharyngeal cancer. N Engl J Med 2010;363:82-4.
24. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-42. (Pubitemid 350146108)
25. Mateos M-V, López-Corral L, Hernández M, Giraldo P, De La Rubia J, de Arriba F, et al. Smoldering multiple myeloma (SMM) at high-risk of progression to symptomatic disease: a phase III, randomized, multi-center trial based on lenalidomide-dexamethasone (Len-Dex) as induction therapy followed by maintenance therapy with len alone vs no treatment. In: Proceedings of the 52nd ASH Annual Meeting and Exposition 2010, updated for 13th Myeloma International Workshop; 2011 May 3-6; Paris, France: International Myeloma Foundation. Abstract nr 1935. Available from: http://www.myeloma-paris2011. com/content/view/21/12/.
26. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
27. Ellisen LW. PARP inhibitors in cancer therapy: promise, progress, and puzzles. Cancer Cell 2011;19:165-7.
28. Huang S, Ren X, Wang L, Zhang L, Wu X. Lung-cancer chemoprevention by induction of synthetic lethality in mutant-KRAS premalignant cells. Cancer Prev Res 2011;4:666-73.
29. Zhang P, Wang J, Shi Y. Structure and mechanism of the S component of a bacterial ECF transporter. Nature 2010;468:717-20.
30. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-80.
31. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361:1164-72.
32. Tang JY, Mackay-Wiggan JM, Aszterbaum M, Lindgren J, Chang K, Coppola C, et al. An investigator-initiated, phase II randomized, double-blind, placebo-controlled trial of GDC-0449 for prevention of BCCs in basal cell nevus syndrome (BCNS) patients. In: Proceedings of the AACR 102nd Annual Meeting; 2011 Apr 3; Orlando, FL. Abstract nr LB-1 Available from: http://www. abstractsonline.com/ Plan/ViewAbstract.aspx?sKey=289dc36e-8df8-4ad3-9887-2b7f4b- 071e8c&cKey=d602b85a-0834-4720-8bac-b37b85a25068&mKey= %7b507D311A-B6EC-436A-BD67-6D14ED39622C%7d.
33. Druker BJ. Perspectives on the development of imatinib and the future of cancer research. Nat Med 2009;15:1149-52.
34. Villani RM, Adlophe C, Palmer J, Waters MJ, Wainwright BJ. Patched1 inhibits epidermal progenitor cell expansion and basal cell carcinoma formation by limiting Igfbp2 activity. Cancer Prev Res 2010;3:1222-34.
35. Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis 2010;31:9-18.
36. Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med 2006;12:1133-8.
37. Willeit P, Willeit J, Mayr A, Weger S, Oberhollenzer F, Brandstatter A, et al. Telomere length and risk of incident cancer and cancer mortality. JAMA 2010;304:69-75.
38. Armanios M. Syndromes of telomere shortening. Annu Rev Genomics Hum Genet 2009;10:45-61.
39. Blackburn EH. Walking the walk from genes through telomere maintenance to cancer risk. Cancer Prev Res 2011;4:473-5.
40. Gu J, Chen M, Shete S, Amos CI, Kamat A, Ye Y, et al. A genome-wide association study identifies a locus on chromosome 14q21 as a predictor of leukocyte telomere length and as a marker of susceptibility for bladder cancer. Cancer Prev Res 2011;4:514-21.
41. Coppé JP, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008;6:2853-68.
42. Epel ES, Blackburn EH, Lin J, Dhabhar FS, Adler NE, Morrow JD, et al. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci U S A 2004;101:17312-5.
43. Sood AK, Lutgendorf SK. Stress influences on anoikis. Cancer Prev Res 2011;4:481-5.
44. Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest 2010;120:1515-23.
45. Zeng Z, Wang W, Yang Y, Chen Y, Yang X, Diehl JA, et al. Structural basis of selective ubiquitination of TRF1 by SCFFbx4. Dev Cell 2010;18:214-25.
46. Beane J, Vick J, Anderlind C, Luo L, Zhang XH, Xiao J, et al. Characterizing the impact of smoking and lung cancer on the airway transcriptome via RNA-seq. Cancer Prev Res 2011;4.
47. Spira A, Beane J, Shah V, Liu G, Schembri F, Yang X, et al. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc Natl Acad Sci U S A 2004;101:10143-8. (Pubitemid 38891209)
48. Beane J, Sebastiani P, Liu G, Brody JS, Lenburg ME, Spira A. Reversible and permanent effects of tobacco smoke exposure on airway epithelial gene expression. Genome Biol 2007;8:R201.
49. Spira A, Beane JE, Shah V, Steiling K, Liu G, Schembri F, et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med 2007;13:361-6. (Pubitemid 46376687)
50. Gustafson AM, Soldi R, Anderlind C, Scholand MB, Qian J, Zhang X, et al. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med 2010;2:26ra25.
51. Irwin ML, McTiernan A, Manson JE, Thomson CA, Sternfeld B, Stefanick ML, et al. Physical activity and survival in postmenopausal women with breast cancer: results from the Women's Health Initiative. Cancer Prev Res 2011;4:522-9.
52. Puterman E, Lin J, Blackburn E, O'Donovan A, Adler N, Epel E. The power of exercise: buffering the effect of chronic stress on telomere length. PLoS One 2010;5:e10837.